

Miastenia Gravis: Inquadramento clinico


DIPARTIMENTO
DI SCIENZE NEUROLOGICHE


SAPIENZA
UNIVERSITÀ DI ROMA



Maurizio Inghilleri


Garantie Laggs	paese	abitanti/5000000	prevalenza (%)
Alter	Charleston (US)	188000	3,20
Okinaka	Fukoaka (Jp)	608000	1,20
Okinaka	Nügata (Jp)	230000	2,60
Gudmundsson	Icelandia	187200	6,40
Hokkanen	Helsinki (Fin)	945000	4,20
Kuroiwa	Hirosaki (Jp)	159000	5,10
Kuroiwa	Aomori (Jp)	244000	3,70
Philips	Virginia (US)	357,159	10,90
Cisneros (5)	Cuba	5782302	4,52
presente	La Palma (Esp)	81507	8,58

























NICOTINIC ACH RECEPTOR AND SUBUNITS






MYASTHENIC & NEUROMUSCULAR JUNCTION (NMJ) DISORDERS

BASIC CONCEPTS	CONGENITAL & FAMILIAL NMJ DISORDERS ²
<u>Acetylcholine receptors (AChRs)</u> <u>AChR structure</u> <u>AChR subunit mutations: α; β; γ; δ</u> <u>Neuromuscular junction (NMJ)</u> <u>Presynaptic</u> <u>Postsynaptic</u>	<u>General features</u> <u>AChRs: Kinetic abnormalities</u> <u>Presynaptic defects</u> <u>Congenital MG + Episodic apnea (Familial infantile): ChAT; 10q11</u> <u>Paucity of synaptic vesicles & Reduced quantal release</u> <u>Congenital Lambert-Eaton-like</u> <u>Episodic ataxia 2: CACNA1A; 19p13</u> <u>Synaptic defects</u> <u>Acetylcholinesterase (AChE) deficiency at NMJs: ColQ; 3p25</u> <u>Postsynaptic defects: AChR disorders</u> <u>Kinetic abnormalities in AChR function</u> <u>↓ Numbers of AChRs at NMJs</u> <u>↑ Response to ACh: Slow AChR channel syndromes</u> <u>Delayed channel closure *</u> <u>Repeated channel reopenings *</u> <u>↓ Response to ACh</u> <u>Fast-channel syndrome: Mode-switching kinetics Δ; ε subunit</u> <u>Fast channel syndrome: Gating abnormality; α or β subunit</u> <u>Fast channel syndrome: Arthrogryposis; δ subunit</u> <u>Also see: ε subunit disorders</u> <u>Normal numbers of AChRs at NMJs: ↓ Response to ACh</u> <u>Fast-channel syndrome: Low ACh-affinity of AChR; ε subunit</u> <u>Fast-channel syndrome: ↓ Probability of channel opening; α subunit</u> <u>High conductance & Fast closure of AChRs</u> <u>↑ Numbers of AChRs at NMJs</u> <u>Slow AChR channel syndrome: SLC26A1M*</u> <u>↓ Numbers of AChRs at NMJs *</u> <u>AChR mutations</u> <u>Usually ε subunit</u> <u>Rare α & β subunit</u> <u>Other hereditary MG syndromes</u> <u>Benign congenital MG & Facial malformations</u> <u>Congenital MG: Other</u> <u>Familial immune</u> <u>Limb-girdle MG: Familial</u> <u>Plectin deficiency: Plectin; 8q24</u>
<u>Childhood MG</u> <u>Drug-induced MG</u> <u>Neonatal Transient MG</u> <u>Ocular</u> <u>Sero-Negative</u> <u>Domestic animals</u> <u>Myasthenic syndrome (Lambert-Eaton)</u> <u>Snake venom toxins</u>	


Origin of Viral Onset Autoimmune Response



T-cells and B-cells attack and destroy a virus. In this case, herpes simplex.




Adult-Onset Autoimmune Response




Antibody Mediated Mechanism: Blockade of Ach

Myasthenic Synapse




Antibody Mediated Mechanism: Crosslinking

Crosslinking by IgG or Fab/ Anti- Fab mechanisms begins accelerated degradation of the post-synaptic terminal.





After cells become crosslinked, signals are sent to speed up decomposition by phagocytosis.



Lysosomes come to help with the decomposition. This continuous process results in the smoothing and simplifying of the post-synaptic terminal.

Normal Receptor Vs. Myasthenic Receptor




The increased distance in the myasthenic receptor drastically cuts down on the chances of Ach finding one of the already scarce receptors. The Ach-esterase then "recycles" the Ach by breaking it into its component parts, acetate and choline.


■ Ach receptor

● Ach vesicle

○ Ach-esterase


○ Mitochondria










REPETITIVE NERVE STIMULATION
NORMAL RESPONSE






REPETITIVE NERVE STIMULATION
DECREMENTING RESPONSE






m. Masseter

n. Trigemino




Decremento positivo nel 78 - 100% (88%)

m. Deltoide





n. Circonflesso







Decremento positivo nel 40 - 100% (65%)

m. Abduttore del V dito

n. Ulnare



Decremento positivo nel 0 - 37% (18%)



MYASTHENIC MUSCULAR SCORE

Mantenere gli arti superiori distesi orizzontalmente
1 punto ogni 10 sec
Max 15
Min 0

Mantenere gli arti inferiori al di sopra del piano del letto in posizione supina
1 punto ogni 5 sec
Max 15
Min 0

Mantenere il capo sopra il piano del letto
Contro resistenza
Senza resistenza
Impossibile
10
5
0

Ajarsi dalla posizione supina
Senza l'aiuto delle mani
Impossibile
10
0

Muscolatura estrinseca degli occhi
Normale
Ptosi
Diplopia
10
5
0

Chiusura delle palpebre
Completa
Debole
Impossibile
10
5
0

Masticazione
Normale
Debole
Impossibile
10
5
0

Deglutizione
Normale
Difficoltosa, senza aspirazione
Difficoltosa, con aspirazione
10
5
0

Fonazione
Normale
Nassale
Difficoltosa
10
5
0

TOTALE / 100







FIG 3.62





GRAZIE PER L'ATTENZIONE